Evidence map›Paper›PMID 41161803›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.

Satoko Oka, Yuina Ueda-Akagi, Takaya Mitsuyoshi, Kazuo Ono

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Satoko OkaDivision of Hematology, Japanese Red Cross Society Wakayama Medical Center, Japan.
Yuina Ueda-AkagiDivision of Hematology, Japanese Red Cross Society Wakayama Medical Center, Japan.
Takaya MitsuyoshiDivision of Hematology, Japanese Red Cross Society Wakayama Medical Center, Japan.
Kazuo OnoDivision of Pathology, Japanese Red Cross Society Wakayama Medical Center, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Owing to the lack of appropriate treatment, TAFRO syndrome often presents with multiple organ dysfunction and fatality. The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway has recently been shown to play an important role in the pathogenesis of inflammation in TAFRO syndrome, and inhibitors of the JAK/STAT pathway may be effective as therapeutic agents for TAFRO syndrome. We herein report the successful treatment using combination therapy with ruxolitinib and ropeginterferon alfa-2b of a case of TAFRO-like syndrome with a long history of polycythemia vera with JAK2 V617F refractory to several treatments.

Indexed as

Castleman DiseaseInterferon alpha-2Janus Kinase InhibitorsPolycythemia VeraDrug Therapy, CombinationHumansInterferon-alphaJanus Kinase 2NitrilesPolyethylene GlycolsPyrazolesPyrimidinesRecombinant ProteinsTreatment OutcomeInterferon-alphaInterferon alpha-2Janus Kinase 2Janus Kinase InhibitorsNitrilespeginterferon alfa-2bPolyethylene GlycolsPyrazolesPyrimidinesRecombinant ProteinsruxolitinibJAK/STAT pathwayropegIFNα2bruxolitinibTAFRO syndrome

Identifiers

PMID41161803
PMCPMC13349462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.